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Leu8 and pro8 oxytocin agonism 
differs across human, macaque, 
and marmoset vasopressin 1a 
receptors
Aaryn Mustoe  1,2*, Nancy A. Schulte2, Jack H. Taylor1,2, Jeffrey A. French1 & Myron L. toews2
Oxytocin (OXT) is an important neuromodulator of social behaviors via activation of both oxytocin 
receptors (OXTR) and vasopressin (AVP) 1a receptors (AVPR1a). Marmosets are neotropical primates 
with a modified OXT ligand (Pro8-OXT), and this ligand shows significant coevolution with traits 
including social monogamy and litter size. Pro8-OXT produces more potent and efficacious responses at 
primate OXTR and stronger behavioral effects than the consensus mammalian OXT ligand (Leu8-OXT). 
Here, we tested whether OXT/AVP ligands show differential levels of crosstalk at primate AVPR1a. We 
measured binding affinities and Ca2+ signaling responses of AVP, Pro8-oXt and Leu8-OXT at human, 
macaque, and marmoset AVPR1a. We found that AVP binds with higher affinity than OXT across 
AVPR1a, and marmoset AVPR1a show a 10-fold lower OXT binding affinity compared to human and 
macaque AVPR1a. Both Leu8-oXt and pro8-OXT produce a less efficacious response than AVP at human 
AVPR1a and higher efficacious response than AVP at marmoset AVPR1a. These data suggest that OXT 
might partially antagonize endogenous human AVPR1a signaling and enhance marmoset AVPR1a 
signaling. These findings aid in further understanding inconsistencies observed following systemic 
intranasal administration of OXT and provide important insights into taxon-specific differences in 
nonapeptide ligand/receptor coevolution and behavior.
Oxytocin (OXT) is a nonapeptide neurohormone involved in regulating many critical reproductive and social 
functions. OXT stimulation leads to contractions of uterine smooth muscle tissue that controls the onset and 
speed of labor, and OXT facilitates the milk-letdown release in mammary tissue for lactation1. OXT signaling in 
the brain is also necessary for regulating motivation for parental, social, and sexual behavior2–4. OXT is produced 
by neurons in the hypothalamic paraventricular and supraoptic nuclei, and OXT neurons are found throughout 
regions of the ‘social brain’5,6. Differences in the expression of OXT receptors (OXTR) are thought to be important 
for species- and individual-level variability in social functioning in primates and rodents7, and regulation of OXT 
signaling is known to have therapeutic benefits in a variety of psychiatric disorders8.
The nonapeptide hormone family is present in nearly all animal lineages9,10, and OXT-like nonapeptides vary 
in structure across phyla at the second, third, fourth, or eighth amino acid (AA) position11. Specifically in mam-
mals OXT plays a central role in reproduction and parental care, and the prevailing belief was that the OXT mol-
ecule was strictly conserved across mammals12. However recent discoveries revealed that primates, particularly 
the primate parvorder Platyrrhini (“New World Monkeys”), constitute an unusual ‘hot-spot’ in OXT structural 
variability within mammals13. Genetic analyses across a broader sample of primate taxa confirmed that the OXT 
ligand has undergone multiple non-synonymous mutations in the coding region of the OXT gene leading to 
seven confirmed OXT ligand variants across Platyrrhini primates14–16. Furthermore, the genetic variability in 
OXT and its corresponding G-protein coupled receptor, OXTR, are significantly associated with positive selection 
for traits including social monogamy and litter size15,16. Interestingly, social monogamy and biparental/cooper-
ative infant care are two OXT-dependent behaviors that are disproportionately overrepresented in Platyrrhini 
primates relative to other primate and mammalian clades11,17.
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OXTR also show high structural variability across primates, particularly in the N-terminus of the receptor15,16, 
which is the receptor region necessary for binding to the tail of the OXT ligand18,19. There is strong evidence for 
coevolution between OXT and its OXTR10,15,16, suggesting that these changes in the OXT ligand are likely con-
sequential for receptor functioning. One tantalizing explanation for this coevolution is that a change in the OXT 
molecule from the ancestral mammalian Leu8-OXT to Pro8-OXT (Pro8 being the most prevalent AA substitution 
from the ancestral OXT) results in a significant structural alteration in the 8th AA position. This change causes a 
‘bent tail’ in the ligand that leads it to be more sterically constrained, and this tail portion of the OXT molecule is 
critical for OXT receptor binding and activation18,20–22.
Whether these evolutionary changes in the OXT ligand lead to important functional differences is an impor-
tant question. Overall, it appears that Pro8-OXT usually produces stronger behavioral and pharmacological out-
comes than Leu8-OXT. When given exogenously in controlled behavioral tests, both Pro8-OXT and Leu8-OXT 
ligands can modulate social behavior, but Pro8-OXT often produces stronger effects11,14. Specifically, in marmo-
sets (Callthrix spp.), a mostly socially monogamous and biparental primate that endogenously express Pro8-OXT, 
Pro8-OXT is more effective at modulating mate and stranger-directed behaviors than the ancestral Leu8-OXT 
ligand. Interestingly, even in rats, a species where males are not parental and parental behavior is OXT-dependent, 
Pro8-OXT was more effective at inducing parental effort from males than Leu8-OXT23. Pharmacological evi-
dence also supports the notion that Pro8-OXT is more efficacious and potent than Leu8-OXT at primate OXTR. 
Pro8-OXT binds with higher affinity at primate OXTR (in both Pro8-OXT and Leu8-OXT expressing primates) 
and produces greater calcium signaling responses compared with Leu8-OXT24,25, but others have reported min-
imal signaling differences23. These data strongly suggest these evolutionary changes in the OXT ligand lead to 
important functional consequences presumably through OXT activation of OXTR.
Although OXT signaling primarily occurs through the activation of OXTR, particularly via Gq-mediated Ca2+ 
mobilization and downstream signaling23,26, OXT also alters physiological and behavioral function by activating 
receptors of the closely related ‘sister’ nonapeptide arginine vasopressin (AVP)23,27,28. OXT activation of vaso-
pressin 1a receptors (AVPR1a) can produce full or partial Gq-mediated Ca2+ signaling responses and can alter 
receptor desensitization and internalization23. OXT activation of AVPR1a leads to diverse behavioral outcomes29, 
and the AVP system has been strongly implicated as an important neural regulator in neurodevelopmental dis-
orders including Autism Spectrum Disorders (ASD)30,31. Given the broad biological functions of OXT and AVP 
receptor signaling, and the fact that these OXT and AVP nonapeptides only differ at AA positions 3 and 8, AA 
substitutions in OXT-like ligands may differentially impact the degree of OXT ligand agonism across primate 
AVPR1a as they do at OXTR.
Because there is considerable crosstalk between OXT and AVP and their canonical receptors, we examined 
whether binding affinities, signaling potencies, and signaling efficacies of OXT isoforms varied across primate 
AVPR1a, with each OXT isoform showing differential levels of agonism at species-specific AVPR1a compared 
to ‘maximal’ AVP-induced responses. If these evolutionary changes in the OXT ligand structure correspond to 
functional alterations in the pharmacological properties of both OXTR and AVPR1a signaling across primates, 
these findings, in turn, may provide important insights into the taxon-specific and receptor-specific patterns 
underlying the OXT- and/or AVP-dependent modulation of social behavior in primates.
Results
125I-OVTA competition binding with OXT and AVP at primate AVPR1a. Saturation binding assays 
were performed to explore species-level differences in binding affinities for the antagonist radioligand 125I-OVTA 
to AVPR1a (SI Fig. 1). Bmax values (i.e., maximal binding) for human, macaque, and marmoset ranged from 
~6.21–12.71 fmol/well with marmosets AVPR1a CHO clone showing the highest Bmax values (Table 1). Overall, 
human, marmoset, and macaque AVPR1a had relatively similar Kd values, ranging from 331–1165 pM (Table 1). 
The affinities for AVPR1a were also similar to those for 125I-OVTA at human, macaque, and marmoset OXTR 
(161–481 pM) published previously (Taylor et al., 2018). These findings confirm that there are only relatively 
small differences in binding affinities for 125I-OVTA among AVPR1a from these three primate species.
In competition binding assays with 125I-OVTA, AVP exhibited higher binding affinity to all primate AVPR1a 
than did either the Leu8-OXT or Pro8-OXT ligands, and Leu8-OXT and Pro8-OXT did not significantly differ 
from each other in affinity (Ki value) at any of the primate AVPR1a (Fig. 1). At human AVPR1a there was a 
significant difference in competitive binding affinity among ligands [F(2,9) = 45.17, p < 0.001]. AVP displayed a 
significantly higher affinity (0.6 nM) than both Leu8-OXT (15.8 nM, p < 0.001) and Pro8-OXT (8.7 nM, p < 0.001), 
but Leu8-OXT and Pro8-OXT did not differ from each other (p = 0.26). At macaque AVPR1a there was a signifi-
cant difference in binding affinity among ligands [F(2,6) = 52.99, p < 0.001]. AVP displayed significantly higher 
affinity (1.2 nM) than both Leu8-OXT (30.0 nM, p < 0.001) and Pro8-OXT (23.8 nM, p < 0.001), but Leu8-OXT 
AVPR1a
Ki 125I-OVTA
Rank Order PotencyAVP Leu8-OXT Pro8-OXT Bmax (fmol/well) Kd (pM)
Human 0.63 ± 0.24 15.78 ± 0.33 8.71 ± 0.37 6.21 1165 AVP > Leu8 = Pro8
Macaque 1.21 ± 0.10 30.02 ± 0.16 23.77 ± 0.17 8.50 331 AVP > Leu8 = Pro8
Marmoset 0.86 ± 0.02 247 ± 0.06 175.9 ± 0.05 12.71 944 AVP > Leu8 = Pro8
Table 1. Binding affinities for ligands at primate AVPR1a. IC50 presented as nM ± Std. Error. Efficacy is 
presented as % maximum AVP response ± Std. Error. Human (n = 3); Macaque (n = 3); Marmoset (n = 5). 
Leu8 = Leu8-OXT; Pro8 = Pro8-OXT.
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and Pro8-OXT did not differ from each other (p = 0.77). Finally, at marmoset AVPR1a there was also a signifi-
cant difference in binding affinity among ligands [F(2,6) = 119.1, p < 0.001]. AVP displayed a significantly higher 
affinity (0.9 nM) than both Leu8-OXT (247 nM, p < 0.001) and Pro8-OXT (176 nM, p < 0.001), but Leu8-OXT 
and Pro8-OXT did not differ from each other (p = 0.69). Interestingly, though AVP affinities were similar for all 
primate AVPR1a, both Leu8-OXT and Pro8-OXT had affinities ~10 fold lower at marmoset AVPR1a compared to 
macaque and human AVPR1a (Table 1).
OXT and AVP stimulation of Ca2+ signaling at primate AVPR1a. Both Leu8-OXT and Pro8-OXT are 
able to activate Ca2+ mobilization in AVPR1a, though in all species the rank order of potencies (Ca2+ EC50 values) 
for OT were significantly lower than for AVP at AVPR1a, and Leu8-OXT and Pro8-OXT were equipotent at all 
three primate AVPR1a (Fig. 2 and Table 2). At human AVPR1a there was a significant difference in Ca2+ response 
potency among ligands [F(2,15) = 49.99, p < 0.001]. AVP was significantly more potent (1.6 nM) at producing a 
Ca2+ response than both Leu8-OXT (69.3 nM, p < 0.001) and Pro8-OXT (36.2 nM, p < 0.001), but Leu8-OXT and 
Pro8-OXT did not differ from each other (p = 0.72). At macaque AVPR1a, there was a significant difference in 
Ca2+ response potency among ligands [F(2,6) = 140.0, p < 0.001]. AVP was significantly more potent (0.3 nM) at 
producing a Ca2+ response than both Leu8 -OXT (31.4 nM, p < 0.001) and Pro8-OXT (17.0 nM, p < 0.001), with 
no difference in potency between Leu8-OXT and Pro8-OXT (p = 0.20). The same pattern was also observed at 
marmoset AVPR1a (AVP = 0.1 nM, Leu8-OXT = 3.8 nM, Pro8-OXT = 3.14 nM) [F(2,6) = 61.91, p < 0.001].
Figure 1. Competition Binding of 125I-OVTA with OXT and AVP at Primate AVPR1a. Binding competition 
curves for AVP, Pro8-OXT, and Leu8-OXT for each of the primate AVPR1a. Increasing concentrations of 
competitor ligand (OXT, AVP) were added to fixed concentration of 125I-OVTA in intact CHO cells expressing 
one of the primate AVPR1a. All values are expressed as percentage of maximal (control) binding in the absence 
of OXT or AVP.
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Though there were no differences in OXT potency (dose needed to produce 50% maximal response, EC50) 
at AVPR1a, there were significant species and ligand differences in the efficacy (maximal magnitude response) 
of OXT agonism at human and marmoset AVPR1a. At human AVPR1a, OXT functioned as a partial agonist 
compared to the canonical ligand AVP [F(2,15) = 18.99, p < 0.001]. Both Leu8-OXT and Pro8-OXT produced 
an approximately 45% maximal Ca2+ response compared to AVP (p < 0.001). Conversely, at marmoset AVPR1a, 
OXT functioned as a superagonist, generating a larger maximal response compared to the canonical ligand AVP 
Figure 2. OXT and AVP Stimulation of Ca2+ Signaling at Primate AVPR1a. Intracellular Ca2+ responses in 
CHO cells expressing each of the primate AVPR1a in response to stimulation with varying concentrations of 
AVP, Pro8-OXT, or Leu8-OXT. All values are expressed as the percentage of the maximal AVP (10−5 M) Ca2+ 
response for each primate species AVPR1a.
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[F(2,6) = 6.03, p < 0.05]. Specifically, the Leu8-OXT maximal response was 118% of that for AVP (p < 0.001), 
and the Pro8-OXT maximal response was 137% of that for AVP (p < 0.001). Compared to Leu8-OXT, Pro8-OXT 
produced a greater maximal Ca2+ response at AVPR1a than Leu8-OXT (p < 0.05). For macaque AVPR1a, AVP, 
Leu8-OXT, and Pro8-OXT all produced equal maximal Ca2+ responses [F(2,6) = 0.23, p = 0.80].
OXT partial antagonism of AVP Ca2+ mobilization at human and marmoset AVPR1a. Partial 
agonists should also exhibit partial antagonism. To confirm this, Leu8-OXT and Pro8-OXT were coadminis-
tered with 10 nM AVP (a concentration of AVP that alone produces approximately 80% of the maximal Ca2+ 
response) for both human and marmoset AVPR1a. For human AVPR1a, both Leu8-OXT and Pro8-OXT caused a 
concentration-dependent decrease in AVP-stimulated Ca2+ mobilization. Both Leu8-OXT and Pro8-OXT at con-
centrations < 1 μM with and without coadministration of 10 nM AVP produced only 50% of the maximal Ca2+ 
mobilization response to AVP, confirming that both OXT ligands act as both partial agonists and partial antag-
onists at human AVPR1a (Fig. 3). For marmoset AVPR1a, OXT did not function as a partial antagonist of AVP, 
(i.e., OXT did not induce inhibition of the Ca2+ signaling response when co-administered with AVP) (Fig. 3). 
Interestingly, in both human and marmoset AVPR1a, Pro8-OXT coadministered with AVP always produced a 
greater maximal response than Leu8-OXT when coadministered with AVP. This occurred even at concentrations 
of OXT that did not produce Ca2+ responses on their own. OXT partial antagonism experiments were not per-
formed in macaque AVPR1a because OXT did not partially agonize or superagonize Ca2+ responses at macaque 
AVPR1a.
Coupling efficiency at primate AVPR1a. We measured a simplified form of coupling efficiency as a ratio 
of the concentration of ligand needed to mobilize Ca2+ responses in primate AVPR1a (potency/EC50) relative to 
the ligand binding affinity (Ki) at AVPR1a (Table 3). This metric provides insight into whether OXT/AVP ligands 
produce equal signaling responses across different receptors in the presence or absence of unbound/spare recep-
tors, i.e., a extra receptors than what is required to produce a maximal response32. Only the marmoset AVPR1a 
showed high coupling efficiency, with EC50 values that were about 1.8 log units higher than their KD values for 
AVPR1a
Ca2+ EC50 Ca2+ Response Efficacy (% Max AVP) Rank Order 
Potency
Rank Order 
EfficacyAVP Leu8-OXT Pro8-OXT Leu8-OXT Pro8-OXT
Human 1.64 ± 0.05 69.34 ± 0.18 36.20 ± 0.25 45.14 ± 3.32 45.21 ± 4.06 AVP > Leu8 = Pro8 AVP > Leu8 = Pro8
Macaque 0.31 ± 0.09) 31.40 ± 0.11 17.02 ± 0.22 84.21 ± 3.25 86.93 ± 6.65 AVP > Leu8 = Pro8 AVP = Leu8 = Pro8
Marmoset 0.05 ± 0.05 3.82 ± 0.05 3.14 ± 0.05 118.20 ± 3.41 137.40 ± 2.75 AVP > Leu8 = Pro8 AVP < Leu8 < Pro8
Table 2. Ca2+ mobilization potencies and efficacies for OXT/AVP at primate AVPR1a. EC50 presented as 
nM ± Std. Error. Efficacy is presented as % maximum AVP response ± Std. Error. Human (n = 6); Macaque 
(n = 3); Marmoset (n = 3).
Figure 3. OXT Partial Antagonism of AVP Ca2+ Mobilization at Human and Marmoset AVPR1a. Intracellular 
Ca2+ responses in CHO cells expressing each of the primate AVPR1a in response to stimulation with varying 
concentrations of Pro8-OXT or Leu8-OXT in the presence or absence of 10−8 M AVP (10 nM). All values are 
expressed as the relative percentage of the AVP (10−8 M) Ca2+ response for each primate species AVPR1a.
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both Leu8-OXT and Pro8-OXT, respectively. Conversely, human AVPR1a showed negative coupling efficiency 
values, suggesting that human AVPR1a require relatively more AVPR1a to produce Ca2+ responses from OXT lig-
ands compared to marmoset AVPR1a. Macaque AVPR1a coupling efficiencies for AVP, Leu8-OXT, and Pro8-OXT 
showed minimal difference (less than one log unit) compared to those for human and marmoset AVPR1a.
Discussion
This study is the first to evaluate potential differences in Leu8-OXT and Pro8-OXT binding affinity, Ca2+ signa-
ling potency and efficacy, OXT partial antagonism, and receptor coupling efficiency across a variety of primate 
AVPR1a. Previous studies have evaluated whether the documented coevolutionary changes in OXT ligands and 
OXTR in Platyrrhini primates would produce demonstrable and unique properties for OXT-OXTR signaling in 
these species23–25. These studies found that changes to the OXT molecule, namely the Leu8 to Pro8 AA substitution 
in OXT, produced only modest changes in binding and signaling across primate OXTR. OXT exhibits a signifi-
cant degree of ‘cross-talk’ with AVP receptors (primarily AVPR1a), and OXT and AVP exhibit potential overlap 
in behavioral outcomes via OXT and AVP signaling in the brain. It is therefore plausible that OXT modifications 
would lead to a functional selective advantage through differences in OXT interactions with AVPR1a. The data 
from this study support three key conclusions: (1) AVP binds with significantly higher affinity than OXT at 
human, marmoset, and macaque AVPR1a, and marmoset receptor AVPR1a show a 10-fold lower OXT binding 
affinity compared to human and macaque AVPR1a. (2) There are no significant differences in binding affinity or 
Ca2+ signaling potency between Leu8-OXT and Pro8-OXT at primate AVPR1a. (3) Both OXT isoforms exhibit 
differential levels of agonism/antagonism across primate AVPR1a, acting as partial agonists and partial antago-
nists at human AVPR1a and as superagonists at marmoset AVPR1a.
The idea that differences in the OXT ligand structure would result in functional differences in primate AVPR1a 
binding and/or signaling properties was only partially supported. While Leu8-OXT and Pro8-OXT showed no 
differences in binding affinity or Ca2+ mobilization potencies at any of the primate AVPR1a, there was a signif-
icant difference in levels of OXT agonism both across primate AVPR1a and between OXT variants. Pro8-OXT 
produced a significantly higher maximal response compared to Leu8-OXT at marmoset AVPR1a. These pharma-
cological findings also partially align with previous work examining effects of Leu8-OXT and Pro8-OXT signaling 
at OXTR. Pro8-OXT exhibited modestly higher potencies than Leu8-OXT at primate OTRs25; Pro8-OXT pro-
duced more efficacious Ca2+ responses at marmoset OXTR but not at human OXTR24; and Pro8-OXT produced 
lower recruitment of β-arrestin and less receptor desensitization and internalization at both human OXTR and 
AVPR1a, where only human receptors were tested23. Perhaps the most compelling finding from this study was 
that OXT exhibits differential agonism at human and marmoset AVPR1a. Similar to OXT signaling at OXTR, 
Pro8-OXT was more efficacious than Leu8-OXT at marmoset but not human AVPR1a. Previous pharmacological 
studies of marmoset OXTR did not explicitly test if different OXT ligands were partial agonists at marmoset and 
human OXTR24, and that study did not make direct comparisons of OXT agonism to AVP agonism at OXTR. 
However, AVP appears to be a full agonist relative to both Leu8-OXT and Pro8-OXT at primate OXTR based on 
data reported across human, marmoset, macaque, and titi monkey OXTR25.
The observation that Leu8-OXT and Pro8-OXT act as a partial agonists/antagonists at human AVPR1a is a 
novel finding. The first reported study evaluating the pharmacological profile of Pro8-OXT at human AVPR1a 
showed that Pro8-OXT is a full agonist at producing Ca2+ responses compared to AVP, while Pro8-OXT was 
only a partial agonist for β-arrestin recruitment at both human AVPR1a or OXTR23. It is unclear what underlies 
the difference in Ca2+ responses from the human AVPR1a tested in this study and the human AVPR1a tested 
previously23. Based on the clear partial agonism at human AVPR1a, we tested whether, as expected, OXT also 
functioned as a partial antagonist of the AVP Ca2+ response at both human and marmoset AVPR1a. Adding 
either OXT isoform along with AVP reduced the AVP Ca2+ response, but only for human AVPR1a. This confirms 
that OXT is a partial antagonist at human AVPR1a but not at marmoset AVPR1a. We further corroborated this 
finding by testing a marmoset AVPR1a clone with lower receptor expression (as indicated by saturation binding 
with 125I-OVTA), and again both OXT ligands functioned as full agonists with slightly lower potency, with the 
Pro8-OXT response greater than for Leu8-OXT, eliminating concerns that species-differences in OXT agonism 
at AVPR1a were due to different expression levels of AVPR1a across species (SI Fig. 2) and/or differences in AVP 
signaling efficacy at 10 nM doses across primate AVPR1a. We also observed that all non-maximal OXT doses 
(<100 nM) of Pro8-OXT coadministered with 10 nM AVP at each primate AVPR1a produced a more efficacious 
agonism than comparable Leu8-OXT doses coadministered with 10 nM AVP, even in the presence of OXT doses 
(<1 nM) that would produce no measurable Ca2+ signaling response on their own. The mechanism underlying 
this finding is currently unclear.
The conclusion that OXT functions as a partial agonist and a partial antagonist for AVP activation of Ca2+ 
signaling responses in human AVPR1a has important implications. Though evidence for endogenously released 
OXT producing functionally important responses at AVP receptors is limited, some studies have shown that stim-
ulating endogenous OXT release can induce social behavioral responses in rodents via AVPR1a33,34. However, a 
AVP Leu8-OXT Pro8-OXT
Human −0.42 −0.64 −0.62
Macaque 0.59 −0.02 0.15
Marmoset 1.28 1.81 1.75
Table 3. Coupling efficiencies for ligands at primate AVPR1a. Calculated as a Potency/Affinity Ratio  
[−Log(Ca2+EC50/Ki)].
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majority of studies that examine the effects of OXT on behavior use exogenous intranasal OXT administration, 
causing systemic distribution and leading to supraphysiological increases in circulating OXT throughout the 
periphery. OXT is known to exert dose-dependent behavioral effects35,36; thus further studies are warranted to 
evaluate whether high doses of OXT, in addition to activating OXTR, might also partially antagonize endogenous 
human AVPR1a signaling, which could aid in further understanding of the inconsistencies observed in behav-
ioral responses following systemic administration of OXT37 and the reported “inverted -U-shaped” relationship 
between OXT dose and behavior38,39.
Moreover, differential OXT agonism at AVPR1a could have important implications for understanding the 
therapeutic potential of nonapeptide treatments in alleviating symptoms associated with neurodevelopmental 
disorders such as autism spectrum disorders (ASD). For instance, animal models of nonapeptide signaling may 
not generalize in a simple way to human clinical trials. The impact of intranasal OXT on behaviorally relevant 
clinical outcomes has shown mixed support in the literature40,41, but recent evidence has shown that peripheral 
use of both a highly selective AVPR1a antagonist and intranasal AVP administration has markedly improved 
behavioral outcomes for individuals with ASD30,31. These findings are important given that similar OXT treatment 
strategies for ASD have shown mixed efficacy42,43, and high doses of OXT could even mitigate potential thera-
peutic benefits of AVPR1a activation in ASD and surely other behavioral contexts as well. Whether the partial 
agonism/antagonism at human AVPR1a explains these anomalies merits further study.
It is also noteworthy that differences in OXTR and AVPR1a functioning are important for our broader under-
standing of the coevolution of nonapeptide signaling system in Platyrrhini primates. While OT acted as a partial 
agonist at human AVPR1a, OXT (both Leu8-OXT and Pro8-OXT) instead acted as a superagonist at marmoset 
AVPR1a. This is especially important from an evolutionary context because the Callitrichid clade has evolved 
widespread Pro8-OXT expression of the OXT ligand, and the Pro8 ligand produces stronger behavioral effects44,45, 
potency and efficacy effects at marmoset OXTR24,25, and efficacy effects at marmoset AVPR1a (this study). It is 
unclear whether the higher agonism and coupling efficiency of OXT at marmoset AVPR1a is an important or 
conserved mechanism underlying the potential coevolution between OXTR and AVPR1a variability with socially 
monogamous phenotypes in primates15,46. More pharmacological and behavioral work utilizing Pro8-OXT and 
other OXT ligands is needed across a broader sampling of primates. Such examples include Leu8-OXT expressing 
titi monkeys that are viewed as socially monogamous and biparental and Pro8-OXT expressing primates such as 
capuchins or squirrel monkeys that are highly social but non-monogamous/biparental. These data combined with 
the important data published on OXTR and AVPR1a central expression profiles in marmoset, titi, macaque, and 
humans7 would serve as a powerful tool to begin utilizing and targeting diverse non-human primate models of 
nonapeptide regulation of social behavioral phenotypes.
Clearly, there are many contributing factors to the ways in which OXT and AVP regulate physiological and 
behavioral outcomes across primates, the relative roles of OXTR and AVPR1a activation, and how well these 
and other in vitro findings translate directly to neural transmission and ultimately behavioral modulation. These 
relationships are difficult to ascertain, especially in light of currently limited access to primate neural tissue and 
primate gene-editing techniques. An important first step is to evaluate whether the pharmacological and physio-
logical findings and principles already established for nonapeptide biology in rodents are divergent or conserved 
across diverse nonhuman primate species. Our findings will serve as a roadmap to target specific pharmacological 
and physiological properties that may underlie species- or individual-level differences in behavioral and social 
phenotypes. Behavioral studies have been at the forefront of this effort and have elucidated many key findings 
about how OXT regulates social behavior in nonhuman primates14,47–49, but many of these studies have yet to 
identify specific neural mechanisms underlying these behavioral effects. Overall, the findings from this study 
provide important molecular insights into species-level differences in nonapeptide ligand/receptor coevolution 
and ‘cross-talk’ between OXT and AVP.
Methods
Primate AVPR1a transfection and cell culture. Chinese hamster ovary (CHO; Female origin) cells 
were purchased from American Type Culture Collecton (Manassas, VA) and cultured at 37 ◦C with 5% CO2 
using Ham’s F12 medium supplemented with 10% fetal bovine serum and 100 units/mL penicillin and 100 µg/ml 
streptomycin. Human, marmoset, and macaque AVPR1a plasmids were purchased from Genscript (Piscataway, 
NJ) in a pcDNA3.1+ vector based on confirmed genetic sequences. CHO cells were transfected using Turbofect 
according to the manufacturer’s instructions and were kept under selective pressure using 400 µg/mL G418 anti-
biotic. Individual clonal lines were generated from batch-transfected cells by plating approximately 10 cells/mL 
(1 cell/100 µL) into 96-well plates. Clonal lines that originated from a single colony were screened using an intact 
cell 125I-ornithine vasotocin analog (125I-OVTA) binding assay and selected for similar receptor expression across 
species, defined as specific radioligand binding. CHO cells showed no endogenous OXTR and AVPR1a binding 
or signaling activity in response to OXT and/or AVP ligands (SI Fig. 3).
Intact cell saturation binding assays. CHO cells expressing primate AVPR1a were plated at 150,000 
cells/mL (15,000 cells per well/100 µL) into 96-well plates and incubated at 37 °C for 48 hours to achieve 80–90% 
confluence. On the day of assay, growth medium was aspirated and cells were quickly washed once with 100 µL 
ice-cold high glucose HEPES-buffered Dulbecco’s Modified Eagle’s Medium containing 0.1% bovine serum albu-
min (HGH-BSA) and then placed on ice. 50 µL of ice-cold HGH-BSA containing 125I-OVTA (PerkinElmer) in 
doubling concentrations (~15 to 2000 pM) was added in triplicate (technical replicates) and incubated for 3 hours 
on ice. 3 hours is the minimum incubation time on ice for 125I-OVTA and 125I-OVTA + AVP/OXT to reach equi-
librium (SI Fig. 4) in CHO cells transfected with human and marmoset AVPR1a. Cells were washed four times 
with 100 µL ice-cold HGH-BSA, solubilized with 100 µL 0.2 N NaOH, and radioactivity quantified with a gamma 
counter. We also counted aliquots of the used binding medium (i.e., free 125I-OVTA) to quantify free radioligand 
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CPM directly, eliminating any concerns about differential depletion of ligand due to differential receptor expres-
sion levels across species or time. Non-specific binding was defined as 125I-OVTA binding occurring in the pres-
ence of excess competitor (10−4 M AVP). Binding affinity for 125I-OVTA was determined after correcting for 
non-specific binding by plotting specific bound/free vs. bound using a single-site binding equation (Graphpad 
Software Inc., La Jolla, CA). Assays were done at least three times on three different days using fresh aliquots of 
125I-OVTA and competitor, and Kd values were averaged across at least three biological replicates.
Intact cell competition binding assays. CHO cells expressing primate AVPR1a were plated at 
150,000 cells/mL (15,000 cells per well/100 ul) into 96-well plates and incubated at 37 °C for 48 hours/grown 
to 80–90% confluence. On the day of assay, growth medium was aspirated and cells were quickly washed once 
with 100 µL ice-cold HGH-BSA and then placed on ice. Then 50 µL of ice-cold HGH-BSA containing ~50,000 
CPM 125I-OVTA were added in triplicate (technical replicates) to all wells in the presence or absence of 10−11 
to 10−5 M Pro8-OXT (CYIQNCPPG-NH2; Anaspec), Leu8-OXT (CYIQNCPLG-NH2; Anaspec) or AVP 
(CYFQNCPRG-NH2; Anaspec), and incubated for three hours on ice. Cells were washed four times with 100 µL 
ice-cold HGH-BSA, solubilized with 100 µL 0.2 N NaOH, and radioactivity was quantified with a gamma counter. 
Half-maximal inhibitory concentrations (IC50) were determined by plotting bound 125I-OVTA vs. competitor 
concentration. IC50 values were then corrected using the Cheng-Prusoff equation with each receptor’s KD for 
125I-OVTA to produce Ki values for the competing ligands. Assays were done at least three times on three different 
days using fresh aliquots of 125I-OVTA and Leu8-OXT, Pro8-OXT, and AVP with at least three biological replicates 
per clone.
ca2+ mobilization assays. CHO cells expressing primate AVPR1a were plated at 150,000 cells/mL (15,000 
cells per well/100 µL) into 96-well plates and incubated at 37 °C for 48 hours/grown to 80–90% confluence. On 
the day of assay, growth medium was aspirated and cells were incubated at 37 °C with 100 µL Fluo-4 Direct 
dye mixed in Fluo-4 Direct Ca2+ Assay Buffer with 5 mM probenecid for ~45 minutes. Using a FlexStation 2 
(Molecular Devices), baseline fluorescence was measured at 37 °C followed by stimulated fluorescence in the 
presence or absence of 10−12 to 10−5 M Pro8-OXT, Leu8-OXT, or AVP (3 × technical replicates). Peak fluorescence 
minus baseline fluorescence was plotted as a function of ligand concentration to determine EC50 values. Assays 
were done at least three times on three different days using fresh aliquots of Leu8-OXT, Pro8-OXT, and AVP for 
three biological replicates per clone. We determined the degree of OXT Ca2+ agonism/antagonism at AVPR1a 
by repeating the same procedures for Leu8-OXT alone, Pro8-OXT alone, and OXT ligands coadministered with 
10−8 M AVP (10 nM) (3 × technical and biological replicates) with concentrations of OXT from 10−10 to 10−5 M 
compared to coadministration of OXT concentrations from 10−10 to 10−4 M together with 10−8 AVP.
Data analyses. Binding affinities for 125I-OVTA at each primate AVPR1a were calculated by subtracting non-
specific binding and then plotting bound 125I-OVTA vs. free 125I-OVTA. Because concentrations of 125I-OVTA 
were not identical from experiment to experiment, technical replicates within each experiment (n = 3) were 
normalized and then corrected using the Cheng-Prusoff equation. Technical replicates were averaged and used 
as biological replicates (n = 3 per clone) to determine and compare Ki values for each ligand within species. 
Differences in Ca2+ mobilization potency (EC50) and maximal response to OXT were determined by normalizing 
OXT-induced (Log M) Ca2+ responses as a percentage of maximal (100%) AVP-induced Ca2+ response. We aver-
aged across technical replicates (n = 3) within each biological replicate and then averaged across the biological 
replicates (n = 3), normalized the data, and tested for significant differences of best-fit LogEC50 using one-way 
ANOVA analyses. Post hoc analyses to assess ligand comparisons (Pro8-OXT vs. Leu8-OXT, Pro8-OXT vs. AVP, 
Leu8-OXT vs. AVP) were performed using Tukey’s posthoc test with a Bonferroni-corrected cutoff to determine 
statistically significant differences in best-fit LogEC50. All best-fit data (Ki, EC50, and Ca2+ maximal responses) 
were analyzed using the nonlinear least squares curve-fitting capabilities of GraphPad Prism.
Data availability
Raw data and clonal cell lines (CHO clonal cell lines expressing either human, macaque, or marmoset AVPR1a) 
are available upon request.
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